Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 4,168 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Clear all
Completed Phase 1 Interventional

Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer

NCT00215709
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel
Drug
Lead sponsor
Geriatric Oncology Consortium
Other
Eligibility
65 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2007 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

NCT03315754
View directory record Official record
Conditions
Localized Prostate Cancer
Interventions
TOOKAD Soluble 4 mg/kg
Drug
Lead sponsor
Steba Biotech S.A.
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 20, 2026, 1:19 PM EDT
Active, not recruiting Not applicable Interventional

Preoperative Pelvic Floor Physical Therapy to Minimize Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate

NCT06179654
View directory record Official record
Conditions
Benign Prostatic Hyperplasia With Outflow Obstruction, Urinary Retention, Lower Urinary Tract Symptoms
Interventions
Preoperative pelvic floor physical therapy
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

NCT04666129
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
Interventions
Relugolix, Abiraterone, Prednisone, Methylprednisolone, Apalutamide, Docetaxel
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 20, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional Results available

Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

NCT01326312
View directory record Official record
Conditions
Prostate Cancer
Interventions
GTx-758 1000mg, Lupron Depot, GTx-758 2000mg
Drug
Lead sponsor
GTx
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
36
States / cities
Phoenix, Arizona • La Mesa, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 20, 2026, 1:19 PM EDT
Suspended Phase 2 Interventional

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

NCT06200103
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Clinical Observation, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 20, 2026, 1:19 PM EDT
Terminated Not applicable Interventional Results available

Minimally Invasive Prostatic Vapor Ablation for the Treatment of BPH in Large Prostates (Rezūm XL)

NCT03605745
View directory record Official record
Conditions
BPH With Urinary Obstruction, BPH, BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms
Interventions
Prostatic Vapor Ablation
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
50 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Scottsdale, Arizona • St. Petersburg, Florida • Jeffersonville, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 20, 2026, 1:19 PM EDT
Active, not recruiting Phase 2 Interventional

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

NCT01786265
View directory record Official record
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions
Abiraterone Acetate, Bicalutamide, Degarelix, Flutamide, Goserelin Acetate, Leuprolide Acetate, Nilutamide, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00513071
View directory record Official record
Conditions
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Interventions
saracatinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Oct 20, 2026, 1:19 PM EDT
Recruiting Phase 2 Interventional

MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer

NCT07644598
View directory record Official record
Conditions
Prostate Cancer, Localized Prostate Carcinoma
Interventions
Microboost SBRT, Whole gland de-escalation 30 Gy, Whole gland de-escalation 35 Gy
Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 20, 2026, 1:19 PM EDT
Terminated Phase 1 Interventional

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

NCT02744287
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Interventions
BPX-601, Rimiducid
Biological · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
13
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 2 Interventional

Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy

NCT00403000
View directory record Official record
Conditions
Prostate Cancer
Interventions
dutasteride
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 20, 2026, 1:19 PM EDT
Completed No phase listed Observational

The AIM Study: Assessing the Impact of Margin Reduction

NCT00754000
View directory record Official record
Conditions
Prostate Cancer
Interventions
Observation
Other
Lead sponsor
Varian, a Siemens Healthineers Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Scottsdale, Arizona • Santa Monica, California • Cape Coral, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 20, 2026, 1:19 PM EDT
Completed No phase listed Observational

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

NCT00897793
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions
venipuncture, radiation therapy
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 2 Interventional

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

NCT00003614
View directory record Official record
Conditions
Prostate Cancer
Interventions
estramustine phosphate sodium, paclitaxel
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
27
States / cities
Chicago, Illinois • Decatur, Illinois • Peoria, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Not applicable Interventional

The Impact of Low Pressure Pneumo in RARP

NCT03370016
View directory record Official record
Conditions
Prostate Cancer
Interventions
Amount of Pneumoperitoneum Pressure applied during RARP
Procedure
Lead sponsor
Metro Health, Michigan
Other
Eligibility
40 Years and older · Male only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Wyoming, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 20, 2026, 1:19 PM EDT
Not listed No phase listed Observational

A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients

NCT06009549
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

NCT02635672
View directory record Official record
Conditions
Neoplasms
Interventions
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 20, 2026, 1:19 PM EDT
Completed No phase listed Observational

Outcomes Comparison of Robotic, Retropubic, and Perineal Prostatectomy

NCT00442000
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostatectomy
Procedure
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older · Male only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 21, 2012 · Synced Oct 20, 2026, 1:19 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS

NCT06906471
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer (Adenocarcinoma), Fluorescence Imaging
Interventions
AS1986NS
Drug
Lead sponsor
Antelope Surgical Solutions, Inc
Industry
Eligibility
18 Years to 90 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 1:19 PM EDT
Terminated Not applicable Interventional

Focal Laser Ablation of Prostate Cancer: A Feasibility Study Using MRI/US Image Fusion for Guidance

NCT06047509
View directory record Official record
Conditions
Prostate Cancer
Interventions
Focal Laser Ablation
Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

NCT00090363
View directory record Official record
Conditions
Prostate Cancer
Interventions
ZD4054 15 mg, Placebo, ZD4054 10 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
7
States / cities
Tucson, Arizona • Los Angeles, California • Gainsville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 20, 2026, 1:19 PM EDT
Active, not recruiting Phase 3 Interventional Results available

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

NCT04689828
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
20
States / cities
Denver, Colorado • Gainesville, Florida • New Orleans, Louisiana + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 20, 2026, 1:19 PM EDT
Recruiting No phase listed Observational

Active Surveillance SNEP Assay Registry Trial for Prostate Cancer

NCT04052048
View directory record Official record
Conditions
Prostate Cancer Aggressiveness
Interventions
Subtraction Normalized Expression of Phagocytes Blood Test
Diagnostic Test
Lead sponsor
Immunis.AI
Industry
Eligibility
40 Years to 80 Years · Male only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 20, 2026, 1:19 PM EDT